After 3 days of treatment with ofloxacin (300 mg given orally once daily), the drug levels in serum and pleural fluid 2 and 4 h after drug administration in patients with tuberculous pleural effusion were assessed by a rapid high-performance liquid chromatography assay. The levels in serum (mean standard error of the mean
[SEM]) were 4.70 0.14 and 4.63 + 0.09 mg/liter 2 and 4 h after administration, respectively, and the levels in pleural fluid (mean SEM) were 3.82 + 0.09 and 4.21 0.08 mg/liter, respectively. The pleural fluid-to-serum ofloxacin ratio at 2 h was 0.82 0.02 (mean ± SEM), and the ratio at 4 h was 0.92 ± 0.02 (mean SEM). This study demonstrated very good penetration of ofloxacin into pleural fluid in tuberculous pleuritis.
Data from studies of levels of fluoroquinolones in lung tissue and pleural fluid have accumulated in the literature. These studies, however, focused only on normal or noninfected material (4, 5, 11) . Studies that examined the levels of these drugs in infected material seem more pertinent to clinical settings and have greater potential therapeutic implications (6, 12) . Ofloxacin, a fluoroquinolone, has been shown to possess distinct activity against Mycobacterium tuberculosis both in vitro and in vivo (9, 10, 12) . In this study, we measured ofloxacin levels in patients with tuberculous pleural effusion.
Twenty-one patients were included in the study. losis chemotherapy. All 21 patients were placed on conventional short-course antituberculosis chemotherapy and 3 days of ofloxacin at a dosage of 300 mg once daily. Informed consent to obtain 5 ml of blood by venipuncture and 10 ml of pleural fluid by fine-needle aspiration 2 and 4 h after ingestion of drugs on the last day of ofloxacin administration, i.e., day 3, was given by each patient. These times were chosen on the assumption that the serum ofloxacin level should be at its peak around 2 h after administration (8) . The pleural fluid samples obtained were all straw colored and free from blood contamination as determined macroscopically. All serum and pleural fluid samples were stored at -40°C and then subjected to a rapid high-performance liquid chromatography assay by a method previously described (3). Each serum and fluid sample was tested in duplicate. In essence, each sample was deproteinated by adding an equal volume of 1.0 M perchloric acid spiked with pipemidic acid as the internal standard. Ten to fifty microliters of the deproteinated sample was then injected into an Ultropac Lichrosorb RP-18 column (250 by 4 mm; 10 ,um) for analysis. The mobile phase (methanol-acetonitrile-0.4 M citric acid [3:1:10]) was delivered at 1.0 mlmin, and ofloxacin was detected with a UV monitor set at a wavelength of 340 nm. This system had detection limits of 0.1 mg/liter for ofloxacin and 0.25 mg/liter for the metabolites of offoxacin, including ofloxacin N-oxide and desmethylofloxacin, with a correlation coefficient of 0.999 and a coefficient of variation of 2.25%. The percent recovery for ofloxacin in this assay was 93.02 (3) .
The characteristics of patients and the serum and pleural fluid ofloxacin concentrations at the times given above are shown in Table 1 . The drug levels in serum at 2 and 4 h (mean ± standard error of the mean [SEMI) were-4.70 + 0.14 and 4.63 ± 0.09 mg/liter, respectively, and the drug levels in pleural fluid at the same times (mean ± SEM) were 3.82 ± 0.09 and 4.21 + 0.08 mg/liter. The pleural fluid-to-serum ofloxacin ratio (mean ± SEM) at 2 h was 0.82 ± 0.02, and the ratio at 4 h was 0.92 ± 0.02.
This study demonstrated that ofloxacin penetrates pleural fluid exceedingly well in the clinical setting of tuberculous pleuritis. In tuberculous pleuritis, fluid can be formed as a result of immunological mechanisms (1), though the culture positivity rate for M. tuberculosis can still range from 25 to 70% (2, 7) . In light of the findings of this study, ofloxacin, a drug with favorable activity against M. tuberculosis, has potential therapeutic value in management of tuberculous pleural effusion.
